Apyx Medical (FRA:BOV) Cyclically Adjusted Revenue per Share: €1.06 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BOV Apyx Medical Corp FRA:BOV
72 GF Score
Price €2.56
GF Value €1.85
! 2 Warning Signs
View Full Analysis

What is Apyx Medical Cyclically Adjusted Revenue per Share?

Apyx Medical FRA:BOV 72 Cyclically Adjusted Revenue per Share is €1.06 as of Jun. 2026. GuruFocus rates FRA:BOV with a GF Score™ of 72/100 and a GF Value™ of €1.85. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Apyx Medical's adjusted revenue per share for the three months ended in Jun. 2026 was €0.275. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.06 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Apyx Medical's average Cyclically Adjusted Revenue Growth Rate was 0.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -2.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Apyx Medical was 5.40% per year. The lowest was -7.10% per year. And the median was -0.30% per year.

As of today (2026-08-18), Apyx Medical's current stock price is €2.56. Apyx Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.06. Apyx Medical's Cyclically Adjusted PS Ratio of today is 2.42.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Apyx Medical was 14.58. The lowest was 0.77. And the median was 3.21.


Apyx Medical  (FRA:BOV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Apyx Medical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.56/1.06
=2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Apyx Medical was 14.58. The lowest was 0.77. And the median was 3.21.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Apyx Medical Cyclically Adjusted Revenue per Share Related Terms


Apyx Medical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Apyx Medical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apyx Medical Cyclically Adjusted Revenue per Share Chart

Apyx Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 1.02 1.07 1.11 0.96

Apyx Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.97 0.96 0.98 1.06

FRA:BOV vs INGN, QSI, QTRX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Apyx Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apyx Medical Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Apyx Medical's Cyclically Adjusted PS Ratio falls into.


FRA:BOV
72GF Score
Apyx Medical Corp FRA:BOV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apyx Medical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Apyx Medical's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.275/333.9520*333.9520
=0.275

Current CPI (Jun. 2026) = 333.9520.

Apyx Medical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.331 241.428 0.458
201612 -0.607 241.432 -0.840
201703 0.254 243.801 0.348
201706 0.283 244.955 0.386
201709 0.072 246.819 0.097
201712 0.094 246.524 0.127
201803 0.084 249.554 0.112
201806 0.116 251.989 0.154
201809 0.090 252.439 0.119
201812 0.144 251.233 0.191
201903 0.149 254.202 0.196
201906 0.176 256.143 0.229
201909 0.202 256.759 0.263
201912 0.221 256.974 0.287
202003 0.132 258.115 0.171
202006 0.112 257.797 0.145
202009 0.173 260.280 0.222
202012 0.275 260.474 0.353
202103 0.212 264.877 0.267
202106 0.271 271.696 0.333
202109 0.293 274.310 0.357
202112 0.433 278.802 0.519
202203 0.329 287.504 0.382
202206 0.282 296.311 0.318
202209 0.266 296.808 0.299
202212 0.344 296.797 0.387
202303 0.328 301.836 0.363
202306 0.362 305.109 0.396
202309 0.324 307.789 0.352
202312 0.388 306.746 0.422
202403 0.272 312.332 0.291
202406 0.326 314.175 0.347
202409 0.299 315.301 0.317
202412 0.355 315.605 0.376
202503 0.214 319.799 0.223
202506 0.242 322.561 0.251
202509 0.269 324.800 0.277
202512 0.388 324.054 0.400
202603 0.247 330.213 0.250
202606 0.275 333.952 0.275

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.06 mean?
Apyx Medical (FRA:BOV) has a Cyclically Adjusted Revenue per Share of €1.06 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Apyx Medical and its competitors.
Is Apyx Medical's Cyclically Adjusted Revenue per Share too high?
Apyx Medical's current Cyclically Adjusted Revenue per Share is €1.06. Overall, Apyx Medical has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Cyclically Adjusted Revenue per Share compare to INGN and QSI?
Apyx Medical's Cyclically Adjusted Revenue per Share of €1.06 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Apyx Medical and its competitors. Apyx Medical's current Cyclically Adjusted Revenue per Share is €1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Apyx Medical (FRA:BOV) has a current Cyclically Adjusted Revenue per Share of €1.06. The stock's GF Value™ is €1.85, compared to a current price of €2.56 — trading 38.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.06. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Apyx Medical (FRA:BOV), the current Cyclically Adjusted Revenue per Share is €1.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apyx Medical (FRA:BOV) Overvalued in 2026?

Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued. The current stock price of €2.56 is trading 38.4% above its estimated GF Value™ of €1.85.

Key valuation signals for FRA:BOV:

  • Cyclically Adjusted Revenue per Share: €1.06
  • GF Value™: €1.85 vs. price of €2.56 (38.4% above fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:BOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apyx Medical Business Description

Other Exchanges APYX:USA
Address 5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score

Get the complete analysis for FRA:BOV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price
€1.85
GF Value